Alector Inc (ALEC)

$5.09

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Alector Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 9.10M → 15.19M (in $), with an average increase of 40.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -44.47M → -41.43M (in $), with an average increase of 7.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 70.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 234.9% return, outperforming this stock by 306.6%

Performance

  • $4.95
    $5.21
    $5.09
    downward going graph

    2.85%

    Downside

    Day's Volatility :5.08%

    Upside

    2.3%

    downward going graph
  • $3.66
    $9.07
    $5.09
    downward going graph

    28.09%

    Downside

    52 Weeks Volatility :59.65%

    Upside

    43.88%

    downward going graph

Returns

PeriodAlector IncSector (Health Care)Index (Russel 2000)
3 Months
-14.45%
-0.4%
0.0%
6 Months
-3.78%
8.5%
0.0%
1 Year
-22.53%
4.2%
-1.2%
3 Years
-71.72%
13.9%
-19.2%

Highlights

Market Capitalization
487.4M
Book Value
$1.58
Earnings Per Share (EPS)
-1.56
Wall Street Target Price
14.5
Profit Margin
-134.34%
Operating Margin TTM
-312.4%
Return On Assets TTM
-13.46%
Return On Equity TTM
-74.81%
Revenue TTM
97.1M
Revenue Per Share TTM
1.16
Quarterly Revenue Growth YOY
5.2%
Gross Profit TTM
-76.8M
EBITDA
-146.0M
Diluted Eps TTM
-1.56
Quarterly Earnings Growth YOY
-0.86
EPS Estimate Current Year
-2.1
EPS Estimate Next Year
-1.77
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.71

Analyst Recommendation

Buy
    70%Buy
    23%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Alector Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
4
4
4
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 184.87%

Current $5.09
Target $14.50

Company Financials

FY18Y/Y Change
Revenue
27.7M
↑ 641.02%
Net Income
-52.2M
↑ 60.86%
Net Profit Margin
-188.78%
↑ 680.83%
FY19Y/Y Change
Revenue
21.2M
↓ 23.33%
Net Income
-99.8M
↑ 91.03%
Net Profit Margin
-470.39%
↓ 281.61%
FY20Y/Y Change
Revenue
21.1M
↓ 0.57%
Net Income
-183.0M
↑ 83.31%
Net Profit Margin
-867.21%
↓ 396.82%
FY21Y/Y Change
Revenue
207.1M
↑ 881.54%
Net Income
-28.0M
↓ 84.69%
Net Profit Margin
-13.53%
↑ 853.68%
FY22Y/Y Change
Revenue
133.6M
↓ 35.48%
Net Income
-133.3M
↑ 375.87%
Net Profit Margin
-99.77%
↓ 86.24%
FY23Y/Y Change
Revenue
97.1M
↓ 27.36%
Net Income
-130.4M
↓ 2.19%
Net Profit Margin
-134.34%
↓ 34.57%
Q3 FY22Q/Q Change
Revenue
14.9M
↓ 81.4%
Net Income
-46.1M
↓ 566.94%
Net Profit Margin
-310.72%
↓ 323.1%
Q4 FY22Q/Q Change
Revenue
14.4M
↓ 2.77%
Net Income
-52.4M
↑ 13.61%
Net Profit Margin
-363.07%
↓ 52.35%
Q1 FY23Q/Q Change
Revenue
16.5M
↑ 14.61%
Net Income
-45.9M
↓ 12.53%
Net Profit Margin
-277.1%
↑ 85.97%
Q2 FY23Q/Q Change
Revenue
56.2M
↑ 239.68%
Net Income
1.4M
↓ 103.0%
Net Profit Margin
2.45%
↑ 279.55%
Q3 FY23Q/Q Change
Revenue
9.1M
↓ 83.8%
Net Income
-44.5M
↓ 3334.55%
Net Profit Margin
-488.25%
↓ 490.7%
Q4 FY23Q/Q Change
Revenue
15.2M
↑ 66.76%
Net Income
-41.4M
↓ 6.84%
Net Profit Margin
-272.77%
↑ 215.48%
FY18Y/Y Change
Total Assets
308.4M
↑ 30.63%
Total Liabilities
405.8M
↑ 40.84%
FY19Y/Y Change
Total Assets
421.9M
↑ 36.83%
Total Liabilities
227.2M
↓ 44.01%
FY20Y/Y Change
Total Assets
488.3M
↑ 15.72%
Total Liabilities
220.7M
↓ 2.84%
FY21Y/Y Change
Total Assets
814.7M
↑ 66.85%
Total Liabilities
513.9M
↑ 132.84%
FY22Y/Y Change
Total Assets
787.6M
↓ 3.32%
Total Liabilities
573.2M
↑ 11.53%
FY23Y/Y Change
Total Assets
621.8M
↓ 21.05%
Total Liabilities
487.7M
↓ 14.92%
Q3 FY22Q/Q Change
Total Assets
837.0M
↓ 5.92%
Total Liabilities
583.9M
↓ 2.86%
Q4 FY22Q/Q Change
Total Assets
787.6M
↓ 5.9%
Total Liabilities
573.2M
↓ 1.84%
Q1 FY23Q/Q Change
Total Assets
748.3M
↓ 4.99%
Total Liabilities
565.3M
↓ 1.37%
Q2 FY23Q/Q Change
Total Assets
708.7M
↓ 5.29%
Total Liabilities
512.4M
↓ 9.36%
Q3 FY23Q/Q Change
Total Assets
672.4M
↓ 5.13%
Total Liabilities
509.8M
↓ 0.51%
Q4 FY23Q/Q Change
Total Assets
621.8M
↓ 7.52%
Total Liabilities
487.7M
↓ 4.35%
FY18Y/Y Change
Operating Cash Flow
127.5M
↓ 817.26%
Investing Cash Flow
-224.1M
↑ 27879.9%
Financing Cash Flow
131.1M
↓ 874406.67%
FY19Y/Y Change
Operating Cash Flow
-99.3M
↓ 177.91%
Investing Cash Flow
-48.9M
↓ 78.19%
Financing Cash Flow
172.4M
↑ 31.42%
FY20Y/Y Change
Operating Cash Flow
-166.7M
↑ 67.9%
Investing Cash Flow
-105.1M
↑ 114.94%
Financing Cash Flow
232.1M
↑ 34.67%
FY21Y/Y Change
Operating Cash Flow
298.6M
↓ 279.06%
Investing Cash Flow
-49.7M
↓ 52.72%
Financing Cash Flow
30.3M
↓ 86.95%
FY22Y/Y Change
Operating Cash Flow
-20.3M
↓ 106.81%
Investing Cash Flow
-159.0M
↑ 220.19%
Financing Cash Flow
4.5M
↓ 85.1%
Q3 FY22Q/Q Change
Operating Cash Flow
-49.1M
↓ 14.6%
Investing Cash Flow
60.5M
↓ 126.8%
Financing Cash Flow
489.0K
↓ 46.03%
Q4 FY22Q/Q Change
Operating Cash Flow
-48.9M
↓ 0.26%
Investing Cash Flow
18.4M
↓ 69.63%
Financing Cash Flow
636.0K
↑ 30.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-48.5M
↓ 0.77%
Investing Cash Flow
88.7M
↑ 382.57%
Financing Cash Flow
1.1M
↑ 69.65%
Q2 FY23Q/Q Change
Operating Cash Flow
-43.0M
↓ 11.42%
Investing Cash Flow
-21.8M
↓ 124.59%
Financing Cash Flow
881.0K
↓ 18.35%

Technicals Summary

Sell

Neutral

Buy

Alector Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alector Inc
Alector Inc
-18.17%
-3.78%
-22.53%
-71.72%
-76.21%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alector Inc
Alector Inc
15.47
NA
NA
-2.1
-0.75
-0.13
NA
1.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alector Inc
Alector Inc
Buy
$487.4M
-76.21%
15.47
-134.34%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • FMR Inc

    13.18%

  • BlackRock Inc

    8.43%

  • Morgan Stanley - Brokerage Accounts

    4.86%

  • Vanguard Group Inc

    4.58%

  • BRAIDWELL LP

    4.26%

  • EcoR1 Capital, LLC

    4.24%

Company Information

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.

Organization
Alector Inc
Employees
244
CEO
Dr. Arnon Rosenthal Ph.D.
Industry
Biotechnology

Discover More

FAQs